A Clinical Study of V940 Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

a study on Bladder Cancer Urinary Bladder Tumor

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around

Description

Summary

Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the inside of the bladder and other parts of the urinary tract, such as part of the kidneys, ureters, and urethra. People with MIUC usually have chemotherapy before surgery, then surgery to remove the cancer. Chemotherapy is a type of medicine to destroy cancer cells or stop them from growing. After surgery, some people receive more treatment to prevent cancer from returning. Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Enfortumab vedotin (EV) is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to learn if giving V940 (the study treatment) with pembrolizumab can prevent MIUC from returning after surgery. V940 (also called mRNA-4157) is designed to treat each person's cancer by helping the person's immune system identify and kill cancer cells based on certain proteins found on those cancer cells.

The goals of this study are to learn if people who receive V940 and pembrolizumab are alive and cancer free longer than those who receive placebo and pembrolizumab, and to learn about the safety of V940, pembrolizumab, and EV, and if people tolerate them.

Official Title

A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)

Details

Enrollment of participants into the Phase 1 Perioperative Cohort of this study is planned to start in approximately February of 2025.

Keywords

Bladder Cancer, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2), Urinary Bladder Neoplasms, Pembrolizumab, Enfortumab Vedotin, Surgery (RC plus PLND)

Eligibility

You can join if…

Open to people ages 18 years and up

The main inclusion criteria include but are not limited to the following:

  • Must provide blood samples per protocol, to enable V940 production, and circulating tumor deoxyribonucleic acid testing
  • Has an Eastern Cooperative Oncology Group performance status of 0 to 2 assessed within 7 days before randomization
  • Must provide a formalin-fixed paraffin-embedded tumor tissue sample for next generation sequencing

Adjuvant Cohort:

  • Has MIUC
  • Has dominant histology of urothelial carcinoma (UC)
  • Has high-risk pathologic disease after radical resection
  • For participants who have not received cisplatin-based neoadjuvant chemotherapy, are ineligible to receive cisplatin according to protocol pre-defined criteria

Perioperative Cohort:

  • Has MIBC
  • Has a histological diagnosis of UC
  • Is deemed eligible for RC and PLND and agrees to undergo curative intent standard RC and PLND and neoadjuvant and adjuvant treatment per protocol
  • Is ineligible to receive cisplatin according to protocol pre-defined criteria

You CAN'T join if...

The main exclusion criteria include but are not limited to the following:

  • Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
  • Has known additional malignancy that is progressing or has required active treatment ≤3 years prior to study randomization
  • Has current pneumonitis/interstitial lung disease
  • Has active infection requiring systemic therapy
  • Has active hepatitis B and hepatitis C virus infection

Adjuvant Cohort:

  • Has received prior systemic anticancer therapy
  • Has received prior neoadjuvant therapy, with the exception of neoadjuvant cisplatin-based chemotherapy for MIUC
  • Has severe hypersensitivity to either V940 or pembrolizumab (MK-3475) and/or any of their excipients

Perioperative Cohort:

  • Has received any prior systemic treatment, cancer vaccine treatment, chemoradiation, and/or radiation therapy treatment for MIBC
  • Has severe hypersensitivity to either V940, pembrolizumab, or EV and/or any of their excipients
  • Has ongoing sensory or motor neuropathy
  • Has active keratitis or corneal ulcerations

Locations

  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro accepting new patients
    Los Angeles California 90095 United States
  • BC Cancer Vancouver ( Site 0004) accepting new patients
    Vancouver British Columbia V5Z 4E6 Canada

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Merck Sharp & Dohme LLC
Links
Merck Clinical Trials Information Plain Language Summary
ID
NCT06305767
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 230 study participants
Last Updated